Vir Biotechnology, Inc. Common Stock (VIR) Financials
Key financial figures for Vir Biotechnology, Inc. Common Stock (Q3 2026).
Vir Biotechnology, Inc. reported revenue of -$188.0 thousand for Q3 FY2026, down 178.3% from the same period a year earlier. The company posted a net loss of $96.3 million, or -$0.57 per share. Free cash flow for the period was -$106.1 million. Across the last 5 reported quarters, quarterly revenue has moved from $240.0 thousand in Q3 FY2025 to -$188.0 thousand in Q3 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Vir Biotechnology, Inc. are on the SentiSense financials page.
- Revenue
- -$188K
- Net Income
- -$96M
- EPS
- $-0.57
- Total Assets
- $1.1B
- Operating Cash Flow
- -$106M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | -$188K | -$96M | -$0.57 | -$106M | |
| Q2 FY2026 | $239M | $80M | $0.47 | 31.22% | $123M |
| Q1 FY2026 | -$29K | -$126M | -$0.85 | -$133M | |
| Q4 FY2025 | $64M | -$43M | -$0.31 | -74.92% | |
| Q3 FY2025 | $240K | -$163M | -$1.17 | -72034.58% | -$168M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $69M | -$438M | -$3.16 | -682.68% | -$397M |
| FY2024 | $74M | -$522M | -$3.83 | -705.37% | -$454M |
| FY2023 | $86M | -$615M | -$4.59 | -767.01% | -$800M |
Frequently asked questions
What was Vir Biotechnology, Inc.'s revenue last quarter?
Vir Biotechnology, Inc. reported revenue of -$188.0 thousand for Q3 FY2026, down 178.3% from the same period a year earlier.
Is Vir Biotechnology, Inc. profitable?
Not in its most recent reported period. Vir Biotechnology, Inc. reported a net loss of $96.3 million for Q3 FY2026.
How much free cash flow did Vir Biotechnology, Inc. generate?
Vir Biotechnology, Inc. generated free cash flow of -$106.1 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Vir Biotechnology, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.